anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objectives. Alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) frequently co-occur, and having one condition worsens the course of the other. Individuals with both disorders exhibit worse functioning across a number of domains than individuals with either disorder alone. Prolonged exposure therapy (PE) is among the most effective treatments for PTSD. PE has been rated as a frontline treatment by multiple guidelines and reviews including the VA/DoD Clinical Practice Guidelines for the treatment of PTSD. However, in studies of individuals with PTSD and AUD, changes in alcohol use are only slightly better than in control or standard care conditions, reductions in PTSD symptoms are sometimes modest relative to studies of PE in PTSD patients without AUD, and rates of drop out from treatment are high. Combining PE with medication to curb drinking shows promise to improve upon the effectiveness of PE for individuals with comorbid AUD and PTSD, although thus far few studies have examined combining psychotherapy and medication. Topiramate is the single medication that has shown effectiveness for both AUD and PTSD and shows promise for reducing drinking among individuals with AUD and PTSD. However, the effect of adding topiramate to PE to treat comorbid AUD/PTSD has yet to be examined. The critical next step is to test a best practice PTSD treatment, PE, together with a promising pharmacological agent, topiramate, which has been found to be effective for both AUD and PTSD. Innovation: This application seeks to shift current clinical practice paradigms. A refinement to existing interventions is proposed through integration of two evidence based treatments.

Methodology. The investigators propose to use a randomized, controlled, double blind study design to examine the effect of adding topiramate (TOP) to a best practice treatment for PTSD, PE. Participants will be 120 male and female Veterans from all services with AUD and PTSD. The investigators' primary aims are to determine the relative efficacy of PE+topiramate, as compared to PE+placebo, in reducing problematic drinking, reducing PTSD symptoms, and improving functioning and quality of life among Veterans with comorbid AUD/PTSD at post-treatment and 3- and 6-month post-treatment follow-up. The investigators will explore the extent to which decreases in drinking and PTSD symptoms lead to improvement in functioning.

The proposed study has the potential to improve functional and psychological recovery for a highly prevalent and highly impaired population of Veterans. This study will test a novel and innovative combination of psychotherapy and medication with the goal of improving the care of Veterans. The successful completion of this project will help change the practices that drive treatment for Veterans who have both AUD and PTSD. The fundamental rationale for this study is to improve the evidence base that informs how patients with AUD and PTSD can attain sustained recovery from both of these disorders. The investigators will also explore whether changes in PTSD symptoms in the PE+TOP condition are partially explained by reductions in alcohol cravings.
A neuromodulator may output stimuli that causes a user to fall asleep faster than the user would in the absence of the stimuli. Alternatively, the stimuli may modify a sleep state or behavior associated with a sleep state, or may cause or hinder a transition from a waking state to a sleep state or from a sleep state to another sleep state. The neuromodulator may take electroencephalography measurements. Based on these measurements, the neuromodulator may detect, in real time, instantaneous amplitude and instantaneous phase of an endogenous brain signal. The neuromodulator may output stimulation that is, or that causes sensations which are, phase-locked with the endogenous brain signal. In the course of calculating instantaneous phase and amplitude, the neuromodulator may perform an endpoint-corrected Hilbert transform. The stimuli may comprise auditory, visual, electrical, magnetic, vibrotactile or haptic stimuli.
The invention relates to a preparation method of a traditional Chinese medicine for treating insomnia type acute glomerulonephritis, belonging to the technical field of preparation methods of traditional Chinese medicines. At present, penicillin is generally adopted for treating insomnia type acute glomerulonephritis, but penicillin can easily cause allergic reaction, and especially allergic shock. The technical scheme adopted in the invention is as follows: taking ossa draconis, concha ostreae, fluorite fluoritum, spina date seed, platycladi seed, polygala tenuifolia, cortex albiziae, tuber fleeceflower stem, valerian, fushen, radix pseudostellariae, black-bone chicken, cabbage, arillus longan, bighead atractylodes rhizome, radix paeoniae alba, American ginseng, angelica sinensis, lotus seed, codonopsis pilosula, sharpleaf galangal fruit, astragalus mongholicus, solomon's seal, polished round-grained rice, rhizome zingiberis, wheat and liquorice, soaking the 27 kinds of traditional Chinese medicines in water, and decocting with slow fire, wherein the decocted liquid medicine is the traditional Chinese medicine for treating insomnia type acute glomerulonephritis. The prepared traditional Chinese liquid medicine has the advantages of short course of treatment and high cure rate. Assistant and guide are achieved so that the function is just right. When the traditional Chinese medicine for treating insomnia type acute glomerulonephritis is applied, adverse reaction, allergic reaction and toxic reaction caused by Western medicine are avoided.
Laparoscopic sleeve gastrectomy (LSG) has become the most commonly performed bariatric procedure worldwide. LSG consists of a longitudinal resection of the stomach leaving the intestines intact, thereby lowering the risk for side-effects due to rerouting of the small bowel. However, gastro-esopageal reflux disease (GERD) has been reported to increase after LSG. Our hypothesis is that GERD is mainly due to intrathoracic migration of the gastric remnant. The aim of this study is to explore if suturing the gastric remnant to the gastrocolic ligament (gastropexy) will prevent intrathoracic migration and thereby reduce the development of reflux.

Patients planned for a sleeve gastrectomy will be invited to participate, and participating patients will be randomized to pexi or no pexi. According to power calculations a total of 550 patients will be randomized in the study. Follow-up will be at six weeks, one-, two- and five years.
BACKGROUND: Non-invasive prenatal testing (NIPT), which can screen for aneuploidies such as trisomy 21, is being implemented in several public healthcare systems across Europe. Comprehensive communication and information have been highlighted in the literature as important elements in supporting women's reproductive decision-making and addressing relevant ethical concerns such as routinisation. Countries such as England and France are adopting broadly similar implementation models, offering NIPT for pregnancies with high aneuploidy probability. However, we do not have a deeper understanding of how professionals' counselling values and practices may differ between these contexts.
METHODS: In this paper, we explore how professionals in England and France support patient decision-making in the provision of NIPT and critically compare professional practices and values. We draw on data from semi-structured interviews with healthcare professionals.
RESULTS: Both English and French professionals emphasised values relating to patient choice and consent. However, understandings and application of these values into the practice of NIPT provision differed. English interviewees placed a stronger emphasis on interpreting and describing the process of counselling patients and clinical care through a "principle" lens. Their focus was on non-directiveness, standardisation, and the healthcare professional as "decision-facilitator" for patients. French interviewees described their approach through a "procedural" lens. Their focus was on formal consent, information, and the healthcare professional as "information-giver". Both English and French professionals indicated that insufficient resources were a key barrier in effectively translating their values into practice.
CONCLUSION: Our findings illustrate that supporting patient choice in the provision of NIPT may be held as an important value in common on a surface level, but can be understood and translated into practice in different ways. Our findings can guide further research and beneficially inform practice and policy around NIPT provision.
The present invention relates to mulberry twig extract prepared into health food for preventing hyperuricemia and gout diseases and drugs for treating hyperuricemia and gout diseases. The mulberry twig extract is prepared from single drug mulberry twig by extraction by 0 to 95% of ethanol water solutions, or solvent of chloroform, acetone, ethyl acetate, carbinol, etc. or the combination of 0 to 95% of ethanol water solutions or solvent under the temperature condition of 10-100 DEG C for one time or more than once time by extracting solution combination and solvent recovery, or the mulberry twig extract is further purified by the following methods that the pH of the extracting solution is regulated into 7.5 to 9.5; the pH of supernatant after centrifugation is regulated into 4 to 6; the extracting solution is precipitated, washed by water to be neutral and dried; the extracting solution is degreased by petroleum ether or gasoline; after being degreased by the petroleum ether or the gasoline, the extracting solution is respectively or orderly extracted by the chloroform, or the ethyl acetate, or the acetone, or the carbinol or water; after being adsorbed by macroporous adsorption resin, the extracting solution is desorbed by 10 to 95% of ethanol water solutions; after being adsorbed by diatomaceous earth, alumina, etc. and eluted by the solvent of the chloroform, the ethyl acetate, the acetone, the carbinol, the ethanol, etc., the extracting solution is concentrated and dried; the extracting solution is separated by polyamide, or silica gel, or ion exchange resin, etc. in the way of column chromatography. The purification methods can be used in the mode of single use or combined use. The obtained mulberry twig extract comprises a large quantity of flavonoid components which comprises rutin, meletin, morin, etc.
BACKGROUND: Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy (RC). Postoperative survival stratification based on radiomics and deep learning (DL) algorithms may be useful for treatment decision-making and follow-up management. This study was aimed to develop and validate a DL model based on preoperative computed tomography (CT) for predicting postcystectomy overall survival (OS) in patients with MIBC.
METHODS: MIBC patients who underwent RC were retrospectively included from four centers, and divided into the training, internal validation, and external validation sets. A DL model incorporated the convolutional block attention module (CBAM) was built for predicting OS using preoperative CT images. The authors assessed the prognostic accuracy of the DL model and compared it with classic handcrafted radiomics model and clinical model. Then, a deep learning radiomics nomogram (DLRN) was developed by combining clinicopathological factors, radiomics score (Rad-score) and deep learning score (DL-score). Model performance was assessed by C-index, KM curve, and time-dependent ROC curve.
RESULTS: A total of 405 patients with MIBC were included in this study. The DL-score achieved a much higher C-index than Rad-score and clinical model (0.690 vs. 0.652 vs. 0.618 in the internal validation set, and 0.658 vs. 0.601 vs. 0.610 in the external validation set). After adjusting for clinicopathologic variables, the DL-score was identified as a significantly independent risk factor for OS by the multivariate Cox regression analysis in all sets (all P <0.01). The DLRN further improved the performance, with a C-index of 0.713 (95% CI: 0.627-0.798) in the internal validation set and 0.685 (95% CI: 0.586-0.765) in external validation set, respectively.
CONCLUSIONS: A DL model based on preoperative CT can predict survival outcome of patients with MIBC, which may help in risk stratification and guide treatment decision-making and follow-up management.
Hydromorphone is known to be subject to abuse. Opiates produce relaxation, indifference to pain and stress, lethargy and euphoria. Patients who receive narcotics regularly for more than a few days may exhibit mild symptoms, which may not be recognized as withdrawal, upon discontinuation of therapy. However, the overwhelming majority of patients who receive opiates for medical reasons do not develop drug-seeking behavior or compulsive drug use. Personality characteristics play a major role in determining which patients are likely to abuse drugs. Hydromorphone must be administered only under close supervision to patients with a history of drug abuse or dependence.
Frozen samples should be thawed at room temperature before use. After the periods mentioned below, any unused solutions or frozen material should be discarded. DO NOT REFREEZE.

NOTE: Solutions of CEFOTAN® (cefotetan for Injection, USP) must not be admixed with solutions containing aminoglycosides. If CEFOTAN® (cefotetan for Injection, USP) and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection. DO NOT ADD SUPPLEMENTARY MEDICATION.

CEFOTAN® (cefotetan for Injection, USP) reconstituted as described above (see DOSAGE AND ADMINISTRATION,Preparation of Solution) maintains satisfactory potency for 24 hours at room temperature (25ºC/77ºF), for 96 hours under refrigeration (5ºC/41ºF), and for at least 1 week in the frozen state (-20ºC/-4ºF). After reconstitution and subsequent storage in disposable glass or plastic syringes, CEFOTAN® (cefotetan for Injection, USP) is stable for 24 hours at room temperature and 96 hours under refrigeration. 

NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
PURPOSE: Consistent with association between photophobia and headache, growing evidence suggests an underlying causal relationship between light sensitivity and central pain. We investigated whether an intervention to regulate light sensitivity by filtering only wavelengths causing difficulties for the specific individual could alleviate headaches/migraines resulting from traumatic brain injury (TBI).
METHODS: Secondary data analysis of a clinical database including N = 392 military personnel (97% men, 3% women), ranging in age from 20 to 51 years, diagnosed with TBI, persistent headaches/migraines, and light sensitivity. The average elapsed time from TBI diagnosis to intervention was 3 years. Headache/migraine severity, frequency, medication use, and difficulties related to daily functioning were assessed pre and 4-12 weeks post-intervention with individualized spectral filters.
RESULTS: Monthly migraine frequency decreased significantly from an average of 14.8 to 1.9, with 74% reporting no migraines post-intervention. Prescription and over-the-counter medication use decreased by more than 70%. Individuals also reported significant improvement in light sensitivity, headaches/migraine severity, and physical and perceptual symptoms.
CONCLUSIONS: Wearing individualized spectral filters was associated with symptom relief, increased subjective quality of reported health and well-being, and decreased objective medication use for TBI-related persistent headaches/migraines. These results support a suggested relationship between dysregulated light sensitivity and central regulation of pain.
Network analysis has become a crucial tool in genetic research, enabling the exploration of associations between genes and diseases. Its utility extends beyond genetics to include the assessment of environmental factors. Unipartite network analysis is commonly used in genomics to visualize initial insights and relationships among variables. Syndromic diseases, such as metabolic syndrome, are characterized by the simultaneous occurrence of various signs, symptoms, and clinicopathological features. Metabolic syndrome encompasses hypertension, diabetes, obesity, and dyslipidemia, and both genetic and environmental factors contribute to its development. Given that relevant data often consist of distinct sets of variables, a more intuitive visualization method is needed. This study applied multipartite network analysis as an effective method to understand the associations among genetic, environmental, and disease components in syndromic diseases. We considered three distinct variable sets: genetic factors, environmental factors, and disease components. The process involved projecting a tripartite network onto a two-mode bipartite network and then simplifying it into a one-mode network. This approach facilitated the visualization of relationships among factors across different sets and within individual sets. To transition from multipartite to unipartite networks, we suggest both sequential and concurrent projection methods. Data from the Korean Association Resource (KARE) project were utilized, including 352,228 SNPs from 8840 individuals, alongside information on environmental factors such as lifestyle, dietary, and socioeconomic factors. The single-SNP analysis step filtered SNPs, supplemented by reference SNPs reported in a genome-wide association study catalog. The resulting network patterns differed significantly by sex: demographic factors and fat intake were crucial for women, while alcohol consumption was central for men. Indirect relationships were identified through projected bipartite networks, revealing that SNPs such as rs4244457, rs2156552, and rs10899345 had lifestyle interactions on metabolic components. Our approach offers several advantages: it simplifies the visualization of complex relationships among different datasets, identifies environmental interactions, and provides insights into SNP clusters sharing common environmental factors and metabolic components. This framework provides a comprehensive approach to elucidate the mechanisms underlying complex diseases like metabolic syndrome.
Composition in the form of water-in-oil emulsion comprising an aqueous phase dispersed in a fatty phase, comprises jasmonic acid derivatives (I) and an emulsifying silicone elastomer that comprises hydrophilic chain and is devoid of 2C oxyalkylene alkyl chain. Composition in the form of water-in-oil emulsion comprising an aqueous phase dispersed in a fatty phase, comprises jasmonic acid derivatives of formula (I) and their optical isomers or salts, and an emulsifying silicone elastomer that comprises hydrophilic chain and is devoid of 2C oxyalkylene alkyl chain. R1 : COOR 3; R2 : optionally saturated, linear 1-8C or branched or cyclic 3-18C hydrocarbyl, preferably pentyl, pentenyl, hexyl or heptyl; and R3 : H or 1-4C alkyl (optionally substituted by OH). An independent claim is included for a non-therapeutic process for making up and/or caring of skin comprising applying a layer of composition to the skin. [Image] ACTIVITY : Nootropic; Dermatological. MECHANISM OF ACTION : None given.
Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
The invention relates to biotechnology. The inventive lactobacteria strain consortium for producing liquid biologically active additives and healthful and dietary sour-milk products comprises Lactobacillus acidophilus 57S (deposited in the VNII genetica in the All-Russian Collection of Industrial Organisms B-5863), Lactobacillus plantarum P-75 (deposited in the VNII genetica in the All-Russian Collection of Industrial Organisms B-3962) and Lactobacillus casei Sb (deposited in the VNII genetica in the All-Russian Collection of Industrial Organisms B-5724) which are taken in a quantity of 2:0.5:0.5. The inventive method for producing the preparation used as a biologically active additive or a starter involves the preparation of a milk nutrition medium, the sterilisation and cooling thereof to a fermentation temperature and the introduction of the seed dose of the above-mentioned lactobacteria strain consortium in a quantity not more than 5 mass%. The fermentation of the product is carried out during a time which is sufficient for a curd formation and the cooling is carried out at a temperature equal to or less than +6°C. Skim milk which is normalised in terms of MSNF up to 13.5-15.0% is used as a milk nutrition medium. Lactopeptone and sodium citrate are also added to the medium at the following component ratio: 3.5-4.5 mass % lactopeptone and 0.15-0.25 mass % sodium citrate, the rest being the skim milk normalised in terms of MSNF up to 13.5-15.0%.
Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.